

Hull and East Riding Prescribing Committee Minutes – Confirmed

Date / Time	Wednesday 24 th May 2017
Venue	The Board Room, ,Health House, Willerby
Chair	Dr S Raise, GP Prescribing Lead, ER
Notes / Action Points	Mrs Sue Greene, Senior Pharmacy Technician – Formulary/Interface, HEY.
Quorate: Yes / No	No
	Mr Kevin McCorry, Senior Pharmacist, ERY, NECS
	Mrs Emma Bagguley, Pharmacist CHCP
	Phil Davis, Head Of Primary Care, Hull, CCG
	Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics, HEY
	Dr Krishna Kasaraneni, Humberside LMC Medical Director
	Mr S Gaines, Senior Principal Pharmacist, HEY
	Dr K Raghunath, GP Prescribing Lead, Hull CCG
	Mrs Jackie Stark, Principal Pharmacist Humber
	Jane Morgan, Acting Senior Principal Pharmacist Interface
	Ms Elizabeth Lyle, Senior Pharmacist – Hull, NECS
	Dr W Chong, Chief Pharmacist, HFT
	Dr Stella Morris (Consultant Psychiatrist and Associate Medical Director in Adult Mental Health Services)
	Dr Libby Rous (Consultant Psychiatrist and Associate Medical Director in Children's and Learning Disability Services)
Apologies	Prof A Morice, Professor of Respiratory Medicine

Tim Allison
 Judith Williamson (Spire)

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2017.05.01	Apologies	As above.				
2017.05.02	Declarations of Interest	None.				
2017.05.03	Minutes of the previous meeting	The Minutes were accepted as a true record.				
2017.05.04	Action Tracker	<p>Pediatric Growth Hormone SCF It was agreed that a meeting be arranged between Commissioners and HEY to agree financial terms, of transfer of care, as this will increase the workload at HEY and extra resources will be needed. Finance dept at HEY are aware of change in commissioners, but the new contract does not include this. It was agreed that GP's are to continue prescribing until the transfer of care has been agreed.</p> <p>Decision making process – Decisions at meetings need both clinical and financial input. Phil Davis had attended for the Hull CCG. Status to be downgraded to Red/Amber – work in progress. No One attended this meeting.</p>	Both CCG's would like this to be a Red drug	<p>To go back to commissioners</p> <p>To go back as Amber on tracker</p>	<p>AR/JM</p> <p>ZN/SR</p>	<p>7/17</p> <p>7/17</p>

	<p>Clinical Network Guidance Acetylcholinesterase Inh Dementia Guideline has been reviewed. Specialist will come to meeting in July to provide feedback.</p> <p>Guanfacine shared care framework- Amendments were done after HERPC discussion, but specialists do not agree. JS will be bringing four consultants and Clinical Director to HERPC in May to discuss. New Action- JM to contact Public Health England</p> <p>Rhinitis Guideline Amendments needed (dexamethasone drops for fluticasone) allergy team at HEY to be contacted for feedback. Update 24/5/17- Contents approved at HERPC but still awaiting feedback from Immunology.</p> <p>Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis, Uterine Fibroids (including pre-op use) or prior to Endometrial Ablation Currently two guidelines on website 'old' one to be removed. New amendments done by consultant to be reviewed</p> <p>Strong Opioid Comparison Guidelines All documents to be merged into one by ER –then to go to Palliative Care Group.</p> <p>Bisphosphonates as Supportive Therapy for Breast Cancer Deferred to May HERPC. Prof Lind to prepare paper</p> <p>Diabetes Formulary GLP-1 Inhibitors Endocrinology to write a recommendation paper. To go to Joint formulary meeting in June</p> <p>Shared Care Issues Tamoxifen GP's are using SCF as a referral document.</p>		<p>Status downgraded to Red/Amber</p> <p>Action Complete</p>	<p>JS</p> <p>JM</p> <p>AR/JM</p> <p>JM/SG</p> <p>EB</p> <p>ML/SG</p> <p>ML</p> <p>KM</p>	<p>5/17</p> <p>7/17</p> <p>7/17</p> <p>7/17</p> <p>7/17</p> <p>7/17</p> <p>7/17</p>
--	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--	--------------------------------------------------------------	------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------

2017.05.05	Traffic Light Status	<ul style="list-style-type: none"> • HEY D&T- • HFT DTC – • CHCP 				
2017.05.06	Feedback From Commissioning Groups	Degarelix- The committee discussed if this could be re classified as an Amber drug .It was felt if a shared care framework was done, would be better for the patients. However there would be cost implications.	.SCF to be done and brought back to HERPC for discussion.	SCF needs writing. JM to contact Mr Myatt	JM	7/17
2017.05.07	Controlled Drug HEY Position	POB circulated the papers to the committee, discussion took place. HEY does not have a contract for drugs used in Primary Care .It was agreed that due to safety issues this would not change, and HEY will keep using the same as Primary Care.	.. .No Further Action			5/17
2017.05.08	Prescribing Guidelines, shared care frameworks for Approval	<ul style="list-style-type: none"> • Guanfacine- Feedback needed from Public Health England re incidents JM to contact • Non-Specialist Analgesia Algorithm for Managing Chronic Non Malignant Pain in Adults noted that the existing Guideline from NICE states ‘Do not use strong opioids’ This would be the only change. • Guidelines for the Prescribing of Stoma Care Appliances in Primary Care- Some minor amendments need to be done. • Guideline for Prescribing Medications Framework for The Treatment and Management of Dementia –Ongoing. The SCF has been updated in line with NICE recommendations. These include the ability of GP’s who have a special interest, or nurse practitioners to be able to prescribe. Strategy would be needed from CCG’s. • Guideline on Prescribing of Gonadorelin Analogues and Gonadotrophin Releasing Hormone Antagonists in the treatment of Prostate Cancer- SCF Approved not guideline. 	KM to send updated version to JM/SG JM to make amendments, and clarify.	SG to upload on website when received	KM/SG JS	7/17 7/17

		<ul style="list-style-type: none"> • Guideline on Prescribing of Gonadorelin (GnRH) Analogues and Progesterone Receptor Modulators in treatment of Endometriosis, Uterine Fibroids (including pre-op use) or prior to Endometrial Ablation. Update- There has been an addition of a flowchart to page 7, that needs some amendments. Also clarification as to who prescribes the first Prescription needed. • Rhinitis guidelines- JM is still waiting for response from Immunology consultant . 	JM to email again		JM	7/17
					JM	7/17
2017.05.09	From MMIG	<p>Valproate in pregnancy alert – Warnings were circulated to the Committee and noted. GP's are already implementing them to patients to patients aged from 10 – 60 years old.</p> <p>Fluticasone Furoate and Vilanterol (Relvar Ellipta) For Patients on DOT therapy only. – This has been approved at HEY D&T for uncontrolled Asthma only. The question was asked if Primary care would be able to help via community Pharmacies or Nurses .It was felt that a protocol would be needed, and an estimate of how many patients would be on this regime, before a decision is made.</p> <p>Oral nutrition supplements on discharge This is to be discussed at the next HERPC</p> <p>Sacubital/Valsartan Discussion has taken place at LMC, Prof Clarke prescribes as the moment. Nurse prescribers can do this if GP's are happy. The issues are 1) He is the only Dr that can prescribe, and he may retire soon? 2) there isn't a SCF and full responsibility would be with the GP. Scarborough already prescribe this.</p>	Discuss at next HERPC		SG	7/17
			More information is needed from Scarborough.	JM to get information and feedback at next HERPC	JM	7/17

2017.05.10	Primary Care Rebate Scheme – Standing Item	None				
2017.05.11	Additional Minutes for Information	<ul style="list-style-type: none"> • a)MMIG (April &May) • b)HEY D&T (April & May) • c)HFT DTC (April) • d)Formulary Sub Group (Nov 16) 	Noted Noted Noted Noted			
2017.05.12	A.O.B	Dexamphetamine –Dr Hammersley A letter was shared with the committee, from Dr Hammersley regarding one of his patients who was taking this medication for Erectile Dysfunction..	There is no evidence that this drug helps with this issue. It is not for this committee to decide.	Dr Raise will write to the GP	SR	7/17
		Next Meeting Wednesday 26 TH July 2017 from 1pm – 3pm Health House, Willerby.				